Clinical trials for cancers of unknown primary patients.
A listing of clinical trials for patients with cancers of unknown primary are listed below.
Therapy: Treatment based on molecular profiling assay — paclitaxel, carboplatin, bevacizumab, erlotinib
Cancer: Carcinoma of Unknown Primary
Phase: II
Sponsor/Manufacturer: Sarah Cannon Research Institute/Genentech
Contact information: John D. Hainsworth, MD, 615-329-7274; jhainsworth@tnonc.com
Avastin (bevacizumab)
Therapy: Cancer: Neuroendocrine Carcinoma
Phase: III
Sponsor/Manufacturer: Southwest Oncology Group, National Cancer Institute
Contact information: James Yao, MD, 713-792-2828; jyao@mdanderson.org or 800-392-1611
Therapy: Taxotere (docetaxel), 5-FU (5-fluorouracil), Platinol (cisplatin)
Cancer: Squamous Cell or Undifferentiated Carcinoma
Phase: II
Sponsor/Manufacturer: M.D. Anderson Cancer Center/Sanofi-Aventis
Contact information: Ehab Y. Hanna, MD, 713-745-2672; eyhanna@mdanderson.org
Therapy: Xeloda (capecitabine)
Cancer: Solid Tumors and Adenocarcinoma of Unknown Primary
Phase: I/II
Sponsor/Manufacturer: Ohio State University Comprehensive Cancer Center
Contact information: OSU Cancer Clinical Trial Matching Service — 866-627-7616; osu@emergingmed.com
Therapy: Vectibix (panitumumab)
Cancer: Squamous Cell Carcinoma of the Head and Neck; Undifferentiated Carcinoma; Adenosquamous Cell Carcinoma
Phase: I
Sponsor/Manufacturer: Dana-Farber Cancer Institute; Brigham and Women’s Hospital; Massachusetts General Hospital/Amgen
Contact information: Lori J. Wirth, MD, 617-632-3090; lwirth@partners.org
Therapy: Nexavar (sorafenib)
Cancer: Advanced Solid Tumors
Phase: II
Sponsor/Manufacturer: University of California Davis
Contact information: UC Davis Clinical Trials Office — 916-734-3089 or Primo N. Lara, MD, 916-734-3772; primo.lara@ucdmc.ucdavis.edu
Therapy: Stereotactic Body Radiotherapy
Cancer: Spinal Neoplasms
Phase: I/II
Sponsor/Manufacturer: M.D. Anderson Cancer Center
Eric L. Chang, MD, 713-563-2300; echang@mdanderson.org
Contact information:
Investigators in clinical trials may be individual physicians, researchers at institutions, or pharmaceutical company representatives. The contact information given here was provided by those running these trials and was accurate at the time of publication. If you get a voice mail, leave the pertinent information. For additional trials, go to www.curetoday.com/trialcheck.
Extending Healing Commitment to a Cancer Community
April 30th 2024It is Meaghan’s unwavering dedication to supporting children and families during a parent’s illness, along with her willingness to take her direct patient care to practices within her professional position and her community service, that allow me to say Meaghan is truly an extraordinary healer deserving of this honor.
Read More
The Essence of Remarkable Cancer Care
April 29th 2024This year marks the 18th year that CURE and Oncology Nursing News have hosted the Extraordinary Healer Award for Oncology Nursing, which gives people the opportunity to recognize and honor the oncology nurses who have made a significant impact on their life.
Read More